Omicron: Covid vaccines should protect against severe illness - but variant can partially evade Pfizer jab

Omicron lab tests from South Africa could evade the Pfizer jab

Existing vaccines should still protect against severe illness from Omicron, a World Health Organisation (WHO) official says.

It comes as the preliminary lab tests of the new variant in South Africa suggest the variant can partially evade the Pfizer vaccine.

What does the study say? 

The study, based on data from double jabbed participants who had a prior infection, found a “very large drop” in how well the vaccine’s antibodies neutralised the new strain, compared to an earlier variant.

However, WHO’s Dr Mike Ryan said there was no sign Omicron would be better at evading vaccines than other variants.

“We have highly effective vaccines that have proved effective against all the variants so far, in terms of severe disease and hospitalisation, and there’s no reason to expect that it wouldn’t be so” for Omicron, Dr Ryan, the WHO’s emergencies director, told AFP news agency.

He also said that initial data suggested Omicron did not make people sicker than the Delta and other strains: “If anything, the direction is towards less severity,” he said.

The South African study, which has not yet been peer-reviewed, tested blood from 12 people given two doses of Pfizer and found the Pfzier/BioTech vaccine may result in up to 40 times fewer neutralising antibodies against Omicron than the original Covid strain.

Professor Alex Sigal, a virologist at the Africa Health Research Institute, said that Omicron’s ability to escape vaccine antibodies is “incomplete”.

Professor Sigal also said the results from 12 people were “better than I expected of Omicron”.

What other protection is there? 

His study also suggested that a combination of vaccinations and prior infection could still neutralise against Omicron, suggesting boosters may bring some significant benefit.

More data on how well the Pfizer jab works against the variant is expected to be released within days.

There is no significant data yet on how well the Moderna, Johnson & Johnson and other jabs hold up against the new Omicron.

A message from the editor:

Thank you for reading. NationalWorld is a new national news brand, produced by a team of journalists, editors, video producers and designers who live and work across the UK. Find out more about who’s who in the team, and our editorial values. We want to start a community among our readers, so please follow us on Facebook, Twitter and Instagram, and keep the conversation going.